{
  "slug": "resveratrol",
  "name": "Resveratrol (trans-resveratrol)",
  "alternate_names": [
    "trans-Resveratrol",
    "3,5,4'-trihydroxy-trans-stilbene",
    "Polygonum cuspidatum extract (knotweed-derived)"
  ],
  "mechanism": [
    "SIRT1 activation reported (deacetylase activity → mitochondrial biogenesis / autophagy / epigenetic modulation); SIRT1-specificity is contested in the literature (specificity questioned by later pharmacology studies)",
    "Endothelial eNOS activation → NO bioavailability (research-context mechanism)",
    "NF-κB inhibition → CRP / IL-6 / TNF-α downregulation (research-context anti-inflammatory pathway)",
    "Nrf2 / AMPK pathway activation → antioxidant defense (mechanistic)",
    "Proposed calorie-restriction mimetic (preclinical framing · not demonstrated in human longevity endpoints)"
  ],
  "target": [
    "SIRT1",
    "NF-kB",
    "eNOS",
    "Nrf2",
    "AMPK"
  ],
  "use_case": [
    "cardiovascular / vascular-function research markers",
    "antioxidant research context",
    "inflammatory-marker research context",
    "glycemic / insulin-sensitivity research populations (T2DM/MetS — disease-population context, not a consumer claim)"
  ],
  "body_system": [
    "CARDIO",
    "ENDO",
    "IMMUNE",
    "CELL",
    "MITO",
    "EPIGEN"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 3,
  "dosage_range": "150-1500 mg/day trans-resveratrol (common RCT range · educational reference) · ≥2 g/day associated with gastrointestinal effects",
  "safety_notes": "Generally well tolerated at ≤500 mg/day in short-term trials; high doses (≥2-2.5 g/day) associated with gastrointestinal side effects. Inhibits multiple cytochrome P450 enzymes (incl. CYP3A4) → potential interaction with prescription medications and anticoagulants. Oral bioavailability is very low (<1%), so systemic exposure at marketed doses is uncertain. Pregnant individuals should avoid supplementation (preclinical placental-flow signal · Bourque/Roberts primate studies). Consult a healthcare provider before use if on prescription medication.",
  "regulatory": {
    "fda": "Legal dietary supplement ingredient (trans-resveratrol) · multiple NDI notifications on file · structure/function claims permissible (antioxidant support / heart health support / healthy aging) with mandatory DSHEA disclaimer · NO disease claims",
    "efsa": "No authorized health claim (Reg 432/2012) · EFSA evaluated and did NOT authorize multiple resveratrol claim applications (insufficient evidence) · marketed as food supplement in some member states",
    "anvisa": "RDC 243/2018 dietary-supplement framework available · no resveratrol-specific Anexo V alegação funcional"
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/resveratrol/",
  "related_goal_slugs": [
    "longevity-stack",
    "heart-health"
  ],
  "related_lifestyle_slugs": [
    "intermittent-fasting",
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}